Skandinaviska Enskilda Banken (SEB)
TPTX

Skandinaviska Enskilda Banken (SEB)’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-10,000
Closed -$753K – 1063
2022
Q2 		$753K Buy
+10,000
New +$444K 0.01% 749

Skandinaviska Enskilda Banken (SEB)'s TPTX Position: Q3 2022 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 10,000 shares — an estimated $753K sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in TPTX in Q2 2022 and held it in 1 quarter. The position peaked at $753K in Q2 2022. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 10,000 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $753K.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • Skandinaviska Enskilda Banken (SEB)'s Turning Point Therapeutics, Inc. Common Stock position peaked at $753K in Q2 2022.
  • 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q3 2022, filed 14 Nov 2022.